Drugs / Sing2016 M2SR H3N2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04960397 | Sep 2021 → Apr 2024 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sing2016 M2SR H3N2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04960397 ↗ |
| Modality | Vaccine | “Novel intranasal live attenuated influenza vaccine” NCT04960397 ↗ |
| Route | Intranasal | “administered intranasally” NCT04960397 ↗ |